Get the latest news, insights, and market updates on GPCR (Structure Therapeutics Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Funding for Risky Biotechs Is Returning
Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years. Jan 12, 2026 - $GPCR
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen top bankers and lawyers. Ahead of the week-long 43rd annual J. Jan 9, 2026 - $GPCR
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On December 19, H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Structure Therapeutics to $90 from $60 with a Buy rating on the shares. The firm suggested that the company’s titration strategy has […] Jan 8, 2026 - $GPCR
Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial
Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See our latest analysis for Structure Therapeutics. The Phase 1 launch for ACCG-2671 comes after a sharp re-rating in Structure Therapeutics, with an 84 percent 1 month share price return feeding into a 163 percent 3 month share price return and 121 percent 1 year total shareholder return. This... Dec 23, 2025 - $GPCR
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company’s lead oral small molecule amylin receptor agonist for the treatment of obesity. ACCG-2671 was designed via the company’s next generation structure-based Dec 17, 2025 - $GPCR
Structure Therapeutics (GPCR) Is Up 121.3% After Strong Phase 2b Data For Oral GLP-1 Aleniglipron - What's Changed
Structure Therapeutics recently reported positive topline Phase 2b and related ACCESS program data for its oral GLP-1 agonist aleniglipron in adults with obesity or overweight, showing clinically meaningful placebo-adjusted weight loss and a safety profile in line with the drug class, and outlined plans to move into Phase 3 trials by mid-2026. A key differentiator was that aleniglipron, a once-daily oral small molecule, paired solid weight loss outcomes with clean liver and cardiac safety... Dec 10, 2025 - $GPCR
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple